ID
34739
Description
Study ID: 104951 Clinical Study ID: 104951 Study Title: A Phase III, double-blind, randomized, controlled study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 vaccine administered intramuscularly according to a 0_ 1_ 6 month schedule in healthy female subjects aged 10 - 14 years. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00290277 https://clinicaltrials.gov/ct2/show/NCT00290277 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: HPV-16/18 L1/AS04 Vaccine Trade Name: N/A Study Indication: Infections, Papillomavirus This form contains information about Contraindications to subsequent vaccination and should be checked at visit 1(Month 0, pre-vacc), 2(Month 1) and 3(Month 6).
Link
https://clinicaltrials.gov/ct2/show/NCT00290277
Keywords
Versions (1)
- 1/25/19 1/25/19 -
Copyright Holder
GlaxoSmithKline
Uploaded on
January 25, 2019
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Evaluation of immunogenicity and safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine in healthy females NCT00290277
Contraindications to subsequent vaccination
- StudyEvent: ODM
Description
Absolute contraindications to further administration of vaccine
Alias
- UMLS CUI-1
- C2368628
- UMLS CUI-2
- C1301624
- UMLS CUI-3
- C0205344
Description
Clinically significant decreased liver or renal function
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0232807
- UMLS CUI [1,2]
- C2985739
- UMLS CUI [1,3]
- C2368628
- UMLS CUI [1,4]
- C0683610
- UMLS CUI [2,1]
- C0232744
- UMLS CUI [2,2]
- C2985739
- UMLS CUI [2,3]
- C2368628
- UMLS CUI [2,4]
- C0683610
Description
Immunodeficient condition
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0021051
- UMLS CUI [1,2]
- C0750484
- UMLS CUI [1,3]
- C0262926
- UMLS CUI [2,1]
- C0021051
- UMLS CUI [2,2]
- C0332147
- UMLS CUI [2,3]
- C0262926
- UMLS CUI [3,1]
- C0021051
- UMLS CUI [3,2]
- C0750484
- UMLS CUI [3,3]
- C0031809
- UMLS CUI [4,1]
- C0021051
- UMLS CUI [4,2]
- C0332147
- UMLS CUI [4,3]
- C0031809
Description
Pregnancy
Data type
boolean
Alias
- UMLS CUI [1]
- C0032961
Description
Hypersensitivity reaction following vaccine administration
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0020517
- UMLS CUI [1,2]
- C2368628
- UMLS CUI [2,1]
- C0042109
- UMLS CUI [2,2]
- C2368628
Description
Anaphylactic reaction following the administration of study/ control vaccine(s).
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0002792
- UMLS CUI [1,2]
- C2368628
Description
A serious adverse event (SAE) is any untoward medical occurrence that: results in death, is life threatening, results in persistent or significant disability / incapacity, requires in-patient hospitalization, prolongation of existing hospitalization or is a congenital anomaly / birth defect in the offspring of a study subject. In addition, important medical events that may jeopardize the subject or may require intervention to prevent one of the other outcomes listed above should be considered serious. (Examples of such events are invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization.) For each serious adverse event the investigator becomes aware of, please fill in a Serious Adverse Event (SAE) report.
Data type
boolean
Alias
- UMLS CUI [1,1]
- C1519255
- UMLS CUI [1,2]
- C1875384
Description
Other significant reactions which in the opinion of the investigator (or designate) preclude further administration of the study/ control vaccine
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0683610
- UMLS CUI [1,2]
- C2368628
- UMLS CUI [1,3]
- C0443286
- UMLS CUI [1,4]
- C2985739
- UMLS CUI [2]
- C0278140
- UMLS CUI [3,1]
- C0038999
- UMLS CUI [3,2]
- C0205082
- UMLS CUI [4,1]
- C0026597
- UMLS CUI [4,2]
- C0449295
- UMLS CUI [4,3]
- C0205082
- UMLS CUI [5]
- C0476474
- UMLS CUI [6,1]
- C0018681
- UMLS CUI [6,2]
- C0205082
- UMLS CUI [7,1]
- C1710276
- UMLS CUI [7,2]
- C0205394
- UMLS CUI [8,1]
- C0853813
- UMLS CUI [8,2]
- C0205394
Description
Contraindications to administration of vaccine at current time
Alias
- UMLS CUI-1
- C2368628
- UMLS CUI-2
- C1301624
- UMLS CUI-3
- C0521116
Description
Acute disease is defined as the presence of a moderate or severe illness with or without fever. Enrolment will be deferred until condition is resolved. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. oral temperature < 37.5 °C (99.5 °F)/axillary temperature < 37.5 °C (99.5 °F).
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0001314
- UMLS CUI [1,2]
- C0150312
- UMLS CUI [1,3]
- C2368628
Description
Oral/axillary temperature ≥37.5 °C (99.5 °F) at the time of vaccination
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0039476
- UMLS CUI [1,2]
- C0442027
- UMLS CUI [1,3]
- C0042196
- UMLS CUI [1,4]
- C0040223
- UMLS CUI [2,1]
- C1531924
- UMLS CUI [2,2]
- C0042196
- UMLS CUI [2,3]
- C0040223
Similar models
Contraindications to subsequent vaccination
- StudyEvent: ODM
C1301624 (UMLS CUI-2)
C0205344 (UMLS CUI-3)
C2985739 (UMLS CUI [1,2])
C2368628 (UMLS CUI [1,3])
C0683610 (UMLS CUI [1,4])
C0232744 (UMLS CUI [2,1])
C2985739 (UMLS CUI [2,2])
C2368628 (UMLS CUI [2,3])
C0683610 (UMLS CUI [2,4])
C0750484 (UMLS CUI [1,2])
C0262926 (UMLS CUI [1,3])
C0021051 (UMLS CUI [2,1])
C0332147 (UMLS CUI [2,2])
C0262926 (UMLS CUI [2,3])
C0021051 (UMLS CUI [3,1])
C0750484 (UMLS CUI [3,2])
C0031809 (UMLS CUI [3,3])
C0021051 (UMLS CUI [4,1])
C0332147 (UMLS CUI [4,2])
C0031809 (UMLS CUI [4,3])
C2368628 (UMLS CUI [1,2])
C0042109 (UMLS CUI [2,1])
C2368628 (UMLS CUI [2,2])
C2368628 (UMLS CUI [1,2])
C1875384 (UMLS CUI [1,2])
C2368628 (UMLS CUI [1,2])
C0443286 (UMLS CUI [1,3])
C2985739 (UMLS CUI [1,4])
C0278140 (UMLS CUI [2])
C0038999 (UMLS CUI [3,1])
C0205082 (UMLS CUI [3,2])
C0026597 (UMLS CUI [4,1])
C0449295 (UMLS CUI [4,2])
C0205082 (UMLS CUI [4,3])
C0476474 (UMLS CUI [5])
C0018681 (UMLS CUI [6,1])
C0205082 (UMLS CUI [6,2])
C1710276 (UMLS CUI [7,1])
C0205394 (UMLS CUI [7,2])
C0853813 (UMLS CUI [8,1])
C0205394 (UMLS CUI [8,2])
C1301624 (UMLS CUI-2)
C0521116 (UMLS CUI-3)
C0150312 (UMLS CUI [1,2])
C2368628 (UMLS CUI [1,3])
C0442027 (UMLS CUI [1,2])
C0042196 (UMLS CUI [1,3])
C0040223 (UMLS CUI [1,4])
C1531924 (UMLS CUI [2,1])
C0042196 (UMLS CUI [2,2])
C0040223 (UMLS CUI [2,3])